Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  PerkinElmer    PKI

PERKINELMER (PKI)
Mes dernières consult.
Most popular
  Report  
End-of-day quote. End-of-day quote  - 04/26
74.2 USD   +1.31%
04/26PERKINELMER : Board Declares Quarterly Dividend
BU
04/23PERKINELMER : Helix Team Up for Exome-Based Personal Genomics
AQ
04/12PERKINELMER : Ex-dividend day for
FA
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

PerkinElmer, Inc. : PerkinElmer Board Declares Quarterly Dividend

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/25/2013 | 10:10pm CEST

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on January 25, 2013. This dividend is payable on May 10, 2013, to all shareholders of record at the close of business on April 19, 2013.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,400 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Investor Relations:
PerkinElmer, Inc.
Tommy J. Thomas, 781-663-5889
[email protected]
or
Media Contact:
PerkinElmer, Inc.
Stephanie R. Wasco, 781-663-5701
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PERKINELMER
04/26PERKINELMER : Board Declares Quarterly Dividend
BU
04/25PERKINELMER INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
04/23PERKINELMER : Helix Team Up for Exome-Based Personal Genomics
AQ
04/19PERKINELMER : Collaborates with Helix to Drive Innovation in Exome-Based Persona..
AQ
04/19PERKINELMER : Trademark Application for "CNGNOME" Filed by PerkinElmer
AQ
04/19PERKINELMER : Appoints James Mock as Chief Financial Officer
AQ
04/19PERKINELMER : to Hold Earnings Call on Monday, April 30, 2018
AQ
04/13PERKINELMER INC : Change in Directors or Principal Officers, Financial Statement..
AQ
04/12PERKINELMER : Prices Offering of Euro-Denominated Senior Notes
AQ
04/12PERKINELMER : Ex-dividend day for
FA
More news
News from SeekingAlpha
04/26PerkinElmer declares $0.07 dividend 
04/19Danaher Q1 beat positive for peers - Evercore ISI 
04/10New finance chief at PerkinElmer 
04/10PerkinElmer teams up with Helix to develop new molecular tests for consumers 
04/04PerkinElmer prices euro debt offering 
Financials ($)
Sales 2018 2 742 M
EBIT 2018 539 M
Net income 2018 291 M
Debt 2018 1 459 M
Yield 2018 0,39%
P/E ratio 2018 27,33
P/E ratio 2019 23,16
EV / Sales 2018 3,48x
EV / Sales 2019 3,21x
Capitalization 8 069 M
Chart PERKINELMER
Duration : Period :
PerkinElmer Technical Analysis Chart | PKI | US7140461093 | 4-Traders
Technical analysis trends PERKINELMER
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 83,2 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Robert F. Friel Chairman, President & Chief Executive Officer
Tajinder Vohra Senior Vice President-Global Operations
Frank Anders Wilson Chief Financial Officer & Senior Vice President
Nicholas A. Lopardo Independent Director
Alexis Platon Michas Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PERKINELMER-0.14%8 069
THERMO FISHER SCIENTIFIC12.95%85 763
DANAHER CORPORATION7.84%69 914
INTUITIVE SURGICAL20.01%49 348
ROYAL PHILIPS9.96%39 965
BOSTON SCIENTIFIC CORPORATION14.97%39 316